NT5E
5'-nucleotidase
As of the edition of 20 October 2026, NT5E (5'-nucleotidase, UniProt P21589) has 9 drugs tested at it and 10 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P21589
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 52
- Disease areas
- Cancer; Lungs and airways; Digestive system; Urinary and reproductive; Hormones; Pregnancy and women's health; Skin and connective tissue; Infections
- Registered trials of its drugs
- 57
Drugs at this target
| Status | Count |
|---|---|
| Active | 4 |
| Went quiet | 1 |
| Stopped | 1 |
| Status not established | 3 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Oleclumab | Active | Phase 3 | none listed |
| Quemliclustat | Active | Phase 3 | none listed |
| AK119 | Active | Phase 2 | none listed |
| Mupadolimab | Stopped | Phase 3 | none listed |
| AK131 | Active | Phase 2 | none listed |
| BMS-986179 | Went quiet | Phase 2 | none listed |
| LY-3475070 | Status not established | Phase 1 | none listed |
| ORIC-533 | Status not established | Phase 1 | none listed |
| Sym024 | Status not established | Phase 1 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Engaged | 5 |
| Undetermined | 3 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route A |
| Corvus Pharmaceuticals | Route A |
The other 8 companies at NT5E
In the product10 companies in all; 8 are not named here, and no score is.
See the 10 companies at NT5E, ranked, with the facts behind eachRequest access. Nothing is shown until you do.